NO20065741L - Framgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser - Google Patents
Framgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelserInfo
- Publication number
- NO20065741L NO20065741L NO20065741A NO20065741A NO20065741L NO 20065741 L NO20065741 L NO 20065741L NO 20065741 A NO20065741 A NO 20065741A NO 20065741 A NO20065741 A NO 20065741A NO 20065741 L NO20065741 L NO 20065741L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- pathway
- reagents
- methods
- disorders
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
- G01N33/743—Steroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Oppfinnelsen omfatter behandling, forebygging og reduksjon av immuninflammatoriske forstyrrelser som omfatter kombinasjonen av et middel som øker signaleringsaktiviteten av en glukokortikoidreseptor (feks. glukokortikoidreseptor-agonist) og et middel som modulerer signaleringsaktiviteten av én eller flere signaleringsveier valgt fra NF-KB-veien, NFAT-veien, AP-l-veien og Elk-l-veien slik at sekresjon eller produksjon av proinflammatorisk cytokin eller hvilken som helst annen inflammatorisk respons, blir redusert. Videre tilveiebringes screeningsmetoder for å identifisere kandidatforbindelser og strategier anvendelige for behandling, forebygging eller reduksjon av slike lidelser.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57175704P | 2004-05-17 | 2004-05-17 | |
PCT/US2005/017117 WO2005115455A2 (en) | 2004-05-17 | 2005-05-16 | Methods and reagents for the treatment of immunoinflammatory disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065741L true NO20065741L (no) | 2007-01-31 |
Family
ID=35451412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065741A NO20065741L (no) | 2004-05-17 | 2006-12-12 | Framgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050271661A1 (no) |
EP (1) | EP1781267A4 (no) |
JP (1) | JP2007538083A (no) |
CN (1) | CN1980649A (no) |
AU (1) | AU2005247403A1 (no) |
BR (1) | BRPI0511272A (no) |
CA (1) | CA2566861A1 (no) |
IL (1) | IL179227A0 (no) |
MX (1) | MXPA06013463A (no) |
NO (1) | NO20065741L (no) |
TW (1) | TW200605864A (no) |
WO (1) | WO2005115455A2 (no) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8263580B2 (en) * | 1998-09-11 | 2012-09-11 | Stiefel Research Australia Pty Ltd | Vitamin formulation |
US20090028850A1 (en) * | 2004-05-14 | 2009-01-29 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
WO2006060819A2 (en) * | 2004-12-03 | 2006-06-08 | The Regents Of The University Of California | Dhmeq as a sensitizing agent for chemotherapy and immunotherapy of resistant cancer cells |
TW200711649A (en) * | 2005-06-17 | 2007-04-01 | Combinatorx Inc | Combination therapy for the treatment of immunoinflammatory disorders |
CN101437501B (zh) * | 2006-03-02 | 2012-09-05 | 阿莱克申药物公司 | 通过抑制补体活性延长同种异体移植物的存活 |
US7964585B2 (en) * | 2006-03-14 | 2011-06-21 | Case Western Reserve University | Composition and method of treating peripheral neuropathy |
US20080167277A1 (en) * | 2006-12-29 | 2008-07-10 | Charles Conrad | Methods of treating skin disorders with caffeic acid analogs |
EP2152276A4 (en) * | 2007-05-09 | 2011-09-14 | Traffick Therapeutics Inc | SCREENING ASSAY FOR IDENTIFYING CORRECTORS FOR PROTEIN TRANSPORT TROUBLESHOOTING |
WO2009061051A1 (en) * | 2007-11-09 | 2009-05-14 | Catholic University Industry Academic Cooperation Foundation | Novel use of capsiate or dihydrocapsidate |
US20090298923A1 (en) * | 2008-05-13 | 2009-12-03 | Genmedica Therapeutics Sl | Salicylate Conjugates Useful for Treating Metabolic Disorders |
US20110250297A1 (en) * | 2008-09-25 | 2011-10-13 | Oronsky Bryan T | Treatment of Hyperproliferative Disorders Using Cardiac Glycosides |
US8450337B2 (en) * | 2008-09-30 | 2013-05-28 | Moleculin, Llc | Methods of treating skin disorders with caffeic acid analogs |
WO2010106082A1 (en) * | 2009-03-16 | 2010-09-23 | Genmedica Therapeutics Sl | Anti-inflammatory and antioxidant conjugates useful for treating metabolic disorders |
CN102421424A (zh) * | 2009-03-16 | 2012-04-18 | 根梅迪卡治疗公司 | 用于治疗代谢性疾病的组合疗法 |
WO2010120726A1 (en) * | 2009-04-13 | 2010-10-21 | The Feinstein Institute For Medical Research | Treatment of inflammatory diseases by inhibiting cold- inducible rna-binding protein (cirp) |
US10813917B2 (en) | 2009-12-11 | 2020-10-27 | Medregen, Llc | Treatment methods utilizing stem cell mobilizers and immunosuppressive agents |
US8466197B2 (en) | 2010-12-14 | 2013-06-18 | Genmedica Therapeutics Sl | Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders |
CN103160560A (zh) * | 2011-12-08 | 2013-06-19 | 清华大学 | 11β,17α,20β,21- 四羟基孕甾-1,4-二烯-3-酮及其制备方法 |
EP2810066B1 (en) * | 2012-01-24 | 2019-07-31 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
US20140275257A1 (en) * | 2013-03-14 | 2014-09-18 | Foundation for the State University of New York | N-acetyl cysteine compositions in the treatment of systemic lupus erythematosus |
CA2925087C (en) | 2013-09-24 | 2024-02-13 | The Feinstein Institute For Medical Research | Peptides inhibiting cold-inducible rna binding protein activity |
US11065252B2 (en) * | 2016-05-06 | 2021-07-20 | Albany Medical College | Treatment of rosacea with P38 and Erk kinase pathway inhibitors |
US20180006888A1 (en) * | 2016-07-01 | 2018-01-04 | Intel Corporation | Analytically directed data collection in sensor network |
KR102563841B1 (ko) * | 2017-01-19 | 2023-08-03 | 티더블유아이 바이오테크놀로지 인코포레이티드 | 면역염증성 피부 장애를 예방 또는 치료하기 위한 방법 및 약학적 조성물 |
CN107156163A (zh) * | 2017-07-14 | 2017-09-15 | 安徽海日生物科技有限公司 | 一种甲基二磺隆和双氟磺草胺复配可分散油悬浮剂及其制备方法 |
CN113545316B (zh) * | 2020-04-24 | 2022-05-17 | 中国科学院上海药物研究所 | 血根碱在制备trpa1通道激动剂中的应用 |
WO2022061171A1 (en) * | 2020-09-18 | 2022-03-24 | Spring Discovery, Inc. | Combination therapies with disulfiram |
CN113876764B (zh) * | 2021-10-29 | 2023-04-14 | 山东良福制药有限公司 | 包含维甲酸的药物组合物在制备治疗特发性血小板减少性紫癜的药物中的用途 |
CN117323442B (zh) * | 2023-08-30 | 2024-05-03 | 广东医科大学 | 一种巨噬细胞靶向二氧化锰纳米系统的制备方法及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5783664A (en) * | 1993-09-17 | 1998-07-21 | Smithkline Beecham Corporation | Cytokine suppressive anit-inflammatory drug binding proteins |
US6288089B1 (en) * | 1998-12-21 | 2001-09-11 | Michael Zawada | Use of kinase inhibitors for treating neurodegenerative diseases |
WO2000059900A1 (en) * | 1999-04-01 | 2000-10-12 | The Board Of Trustees Of The University Of Arkansas | P38mapk inhibitor and uses thereof |
DE60233414D1 (de) * | 2001-07-09 | 2009-10-01 | Combinatorx Inc | Kombinationen für die behandlung entzündlicher erkrankungen |
JP2005527639A (ja) * | 2001-11-02 | 2005-09-15 | インサート セラピューティクス インコーポレイテッド | Rna干渉の治療的利用のための方法及び組成物 |
US20040110755A1 (en) * | 2002-08-13 | 2004-06-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions |
BR0314713A (pt) * | 2002-09-24 | 2005-07-26 | Combinatorx Inc | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias |
CA2508217A1 (en) * | 2002-12-17 | 2004-07-15 | Pharmagenesis, Inc. | Triptolide derivatives as immunomodulators and anticancer agents |
US6943259B2 (en) * | 2003-02-25 | 2005-09-13 | Pharmagenesis, Inc. | Halogenated triptolide derivatives as immunomodulators and anticancer agents |
BRPI0414719A (pt) * | 2003-09-24 | 2006-11-21 | Combinatorx Inc | regimes terapêuticos para administrar combinações de fármacos |
-
2005
- 2005-05-16 CN CNA2005800230040A patent/CN1980649A/zh active Pending
- 2005-05-16 MX MXPA06013463A patent/MXPA06013463A/es not_active Application Discontinuation
- 2005-05-16 EP EP05750679A patent/EP1781267A4/en not_active Withdrawn
- 2005-05-16 JP JP2007527344A patent/JP2007538083A/ja not_active Withdrawn
- 2005-05-16 WO PCT/US2005/017117 patent/WO2005115455A2/en active Application Filing
- 2005-05-16 BR BRPI0511272-9A patent/BRPI0511272A/pt not_active IP Right Cessation
- 2005-05-16 AU AU2005247403A patent/AU2005247403A1/en not_active Abandoned
- 2005-05-16 US US11/130,426 patent/US20050271661A1/en not_active Abandoned
- 2005-05-16 CA CA002566861A patent/CA2566861A1/en not_active Abandoned
- 2005-05-17 TW TW094115881A patent/TW200605864A/zh unknown
-
2006
- 2006-11-13 IL IL179227A patent/IL179227A0/en unknown
- 2006-12-12 NO NO20065741A patent/NO20065741L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2005247403A1 (en) | 2005-12-08 |
MXPA06013463A (es) | 2007-03-01 |
IL179227A0 (en) | 2007-03-08 |
BRPI0511272A (pt) | 2007-12-04 |
EP1781267A2 (en) | 2007-05-09 |
CA2566861A1 (en) | 2005-12-08 |
WO2005115455A2 (en) | 2005-12-08 |
WO2005115455A3 (en) | 2006-08-10 |
EP1781267A4 (en) | 2009-03-11 |
US20050271661A1 (en) | 2005-12-08 |
JP2007538083A (ja) | 2007-12-27 |
CN1980649A (zh) | 2007-06-13 |
TW200605864A (en) | 2006-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065741L (no) | Framgangsmater og reagenser for behandling av immunoinflammatoriske forstyrrelser | |
NO20056046L (no) | Oralt dispergerbar flerlags tablett | |
NO20072352L (no) | Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet | |
NO20050074L (no) | Modulatorer for glukocorticoidreseptoren og metode | |
CY1119318T1 (el) | Κινητες οθονες και συναφεις μεθοδοι | |
NO20055306L (no) | GITR ligand og GITR ligand relaterte molekyler og antistoffer og anvendelse derav | |
NO20061906L (no) | Terapeutisk middel for mesoteliom | |
NO20064225L (no) | Anording og fremgangsmate for hivkompensering | |
NO20065984L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
NO20014986D0 (no) | 4,5-diaryl-3(2H)-furanonderivater som cyklooksygenase-2- inhibitorer | |
NO20065983L (no) | Forbindelser og sammensetninger som PPAR modulatorer | |
NO20082699L (no) | Immunoglobuliner | |
EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
NO20070390L (no) | Triterpen-inneholdende oleogel-dannende middel, triterpen-inneholdende oleogel og fremgangsmate for fremstilling av en triterpen-inneholdende oleogel | |
NO20081014L (no) | Sammensetninger | |
NO20064715L (no) | Deteksjon, isolering og anvendelse av renalase (monoamin aksidase C) | |
NO20073369L (no) | Modulatorer av muskarinreseptorer | |
ITRM20030236A0 (it) | Procedimento ed apparecchio per la simulazione di slittamenti su cavalletti di collaudo di veicoli. | |
WO2006024958A3 (en) | Cannabinoid compositions and methods of use thereof | |
ATE457309T1 (de) | Modulatoren von peripheren 5-ht-rezeptoren | |
WO2004110385A3 (en) | Modulators of the glucocorticoid receptor and method | |
WO2004045545A3 (en) | Compositions and methods for the treatment of cancer, screening of putative anti-cancer compounds, and assessing cancer progression | |
ATE443283T1 (de) | Doppelseitiger tourbillon | |
EA200602083A1 (ru) | Новые пиперазиновые производные диалкилоксиндолов | |
NO20041710D0 (no) | Anordning og system for slukking av dekksbranner pa et skip. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |